Less Ads, More Data, More Tools Register for FREE

Biotech Growth Trust In Mixed Performance Against Benchmark

Thu, 07th Aug 2014 11:31

LONDON (Alliance News) - The Biotech Growth Trust PLC Thursday said its net asset value per share rose by 5.4%, compared with a rise of 6.1% in its benchmark, the NASDAQ Biotechnology Index, measured in sterling terms, over the three months to the end of June.

The company's share price rose by 5.9%, and ended the period on a 6.0% discount to its NAV.

From the end of June to August 5, the company's NAV fell by 0.1% and its share price fell by 1.7%. The benchmark experienced a fall of 0.7% over the same period.

By Samuel Agini; samagini@alliancenews.com; @samuelagini

Copyright 2014 Alliance News Limited. All Rights Reserved.

Biotech Gwth

Shares in this article

Related News

Apellis investors respond to USD5.60 billion Biogen acquisition
1 Apr 2026

Apellis investors respond to USD5.60 billion Biogen acquisition

(Alliance News) - Biotech Growth Trust PLC, International Biotechnology Trust PLC, ad RTW Biotech Opportunities Ltd have all noted the agreement annou...

Biotech Growth Trust appoints former UKHSA head Jenny Harries to board
17 Sep 2025

Biotech Growth Trust appoints former UKHSA head Jenny Harries to board

(Alliance News) - Biotech Growth Trust PLC on Wednesday said Jenny Harries has been appointed an independent non-executive director, as of Tuesday.